Literature DB >> 21731191

Continual Reassessment and Related Dose-Finding Designs.

John O'Quigley1, Mark Conaway.   

Abstract

During the last twenty years there have been considerable methodological developments in the design and analysis of Phase 1, Phase 2 and Phase 1/2 dose-finding studies. Many of these developments are related to the continual reassessment method (CRM), first introduced by O'Quigley, Pepe and Fisher (1990). CRM models have proven themselves to be of practical use and, in this discussion, we investigate the basic approach, some connections to other methods, some generalizations, as well as further applications of the model. We obtain some new results which can provide guidance in practice.

Entities:  

Year:  2010        PMID: 21731191      PMCID: PMC3128794          DOI: 10.1214/10-STS332

Source DB:  PubMed          Journal:  Stat Sci        ISSN: 0883-4237            Impact factor:   2.901


  34 in total

1.  Dose-finding designs for HIV studies.

Authors:  J O'Quigley; M D Hughes; T Fenton
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Continual reassessment designs with early termination.

Authors:  John O'Quigley
Journal:  Biostatistics       Date:  2002-03       Impact factor: 5.899

3.  Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.

Authors:  J O'Quigley
Journal:  Biometrics       Date:  1992-09       Impact factor: 2.571

4.  A curve-free method for phase I clinical trials.

Authors:  M Gasparini; J Eisele
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

5.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

6.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

7.  A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity.

Authors:  John Whitehead; Helene Thygesen; Anne Whitehead
Journal:  Stat Med       Date:  2010-07-30       Impact factor: 2.373

8.  Identifying the most successful dose (MSD) in dose-finding studies in cancer.

Authors:  Sarah Zohar; John O'Quigley
Journal:  Pharm Stat       Date:  2006 Jul-Sep       Impact factor: 1.894

9.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

10.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.

Authors:  Thomas M Braun
Journal:  Control Clin Trials       Date:  2002-06
View more
  15 in total

1.  Performance of toxicity probability interval based designs in contrast to the continual reassessment method.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

2.  Design considerations for dose-expansion cohorts in phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

Review 3.  Implementation of adaptive methods in early-phase clinical trials.

Authors:  Gina R Petroni; Nolan A Wages; Gautier Paux; Frédéric Dubois
Journal:  Stat Med       Date:  2016-02-29       Impact factor: 2.373

4.  Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

Authors:  Mahesh Kb Parmar; Matthew R Sydes; Fay H Cafferty; Babak Choodari-Oskooei; Ruth E Langley; Louise Brown; Patrick Pj Phillips; Melissa R Spears; Sam Rowley; Richard Kaplan; Nicholas D James; Timothy Maughan; Nicholas Paton; Patrick J Royston
Journal:  Clin Trials       Date:  2017-08-22       Impact factor: 2.486

5.  Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Authors:  Ying Kuen Cheung
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

6.  Sequential monitoring of Phase I dose expansion cohorts.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2016-02-07       Impact factor: 2.373

7.  The Impact of Early-Phase Trial Design in the Drug Development Process.

Authors:  Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

8.  Selection of the initial design for the two-stage continual reassessment method.

Authors:  Xiaoyu Jia; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-07       Impact factor: 1.051

9.  Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.

Authors:  Lingyun Ji; Juan Pablo Lewinger; Mark Krailo; Susan Groshen; David V Conti; Shahab Asgharzadeh; Richard Sposto
Journal:  Pharm Stat       Date:  2019-06-25       Impact factor: 1.894

10.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Authors:  Anuradha Banerjee; Regina I Jakacki; Arzu Onar-Thomas; Shengjie Wu; Theodore Nicolaides; Tina Young Poussaint; Jason Fangusaro; Joanna Phillips; Arie Perry; David Turner; Michael Prados; Roger J Packer; Ibrahim Qaddoumi; Sridharan Gururangan; Ian F Pollack; Stewart Goldman; Lawrence A Doyle; Clinton F Stewart; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.